Home Infusion Therapy Medicare Audit Readiness: Drug, Nursing, and Professional Services Documentation

How Medicare covers and audits home infusion therapy across the DME external infusion pump benefit and the home infusion therapy services benefit, including 2026 payment rates, qualified supplier and plan of care requirements, and the drug, nursing, and professional services documentation that supports payment.

KNOWLEDGE CENTER

11/15/202612 min read

Home infusion therapy allows patients to receive intravenous and subcutaneous medications, such as antibiotics, inotropes, chemotherapy, immune globulin, and pain management drugs, in their homes rather than in hospitals or infusion centers. It can reduce costs and improve quality of life. In Medicare, however, home infusion is covered through a patchwork of benefits, each with its own coverage criteria, billing rules, and documentation requirements. That complexity makes home infusion a recurring audit target and a frequent source of denials.

Medicare fee-for-service covers home infusion through several channels. The durable medical equipment (DME) benefit covers external infusion pumps, the drugs administered through them, and related supplies when coverage criteria are met. Since January 1, 2021, the home infusion therapy services benefit created by the 21st Century Cures Act pays qualified home infusion therapy suppliers for professional services, including nursing, patient training and education, and monitoring, associated with drugs administered through covered pumps. A separate benefit covers home intravenous immune globulin services for certain patients with primary immune deficiency. Many other infused drugs are covered under Medicare Part D, which pays for the drug but not for the professional services or supplies. Home health agencies may also provide nursing to infusion patients under the home health benefit.

The landscape continues to evolve. CMS updated home infusion therapy services payment rates for 2026, and the Consolidated Appropriations Act, 2026 directed CMS to expand DME coverage of certain external infusion pumps and associated drugs. CMS implemented that expansion in the CY 2027 home health final rule, with an exception beginning April 1, 2027. Legislation to address structural limitations in the benefit remains pending in Congress. CMS also publishes periodic monitoring reports on home infusion therapy utilization, supplier characteristics, and beneficiary characteristics, which signal continued attention to how the benefit is used and billed.

This article explains how Medicare covers home infusion, what auditors examine, and the documentation needed for drugs, nursing, and professional services. It is educational and not legal advice. Coverage policies differ by benefit and contractor, so suppliers should confirm current requirements with their DME MAC or A/B MAC and experienced healthcare counsel.

The Medicare Home Infusion Framework

The DME External Infusion Pump Benefit

External infusion pumps are covered as DME when the requirements of the External Infusion Pumps Local Coverage Determination and related policy article are met. The LCD identifies the drugs and clinical conditions for which a pump is considered reasonable and necessary, such as certain parenteral inotropic therapy for heart failure, certain chemotherapy regimens, subcutaneous immune globulin for specified conditions, and certain pain management therapies. When a pump is covered, the drug administered through it and related supplies are also covered under the DME benefit and are billed to the DME MAC.

DME claims must meet general DME documentation requirements, including a standard written order, medical records supporting coverage criteria, proof of delivery, and, for continued coverage, documentation of continued medical need and use. Drugs not listed in the LCD for pump administration are generally not covered under Part B through the DME benefit, even if they are administered at home by a pump, although the 2026 legislative expansion broadens coverage in certain circumstances beginning in 2027.

The Home Infusion Therapy Services Benefit

The home infusion therapy services benefit, codified at section 1861(iii) of the Social Security Act and implemented at 42 CFR Part 414, Subpart P, and 42 CFR Part 486, Subpart I, pays for professional services furnished by a qualified home infusion therapy supplier in the patient's home. Covered services include professional services such as nursing, training and education not otherwise covered under the DME benefit, remote monitoring, and other monitoring services. The benefit applies to drugs administered through a pump covered under the DME benefit, and drugs are grouped into three payment categories:

• Category 1, covering certain intravenous anti-infective, pain management, chelation, pulmonary hypertension, and inotropic drugs.

• Category 2, covering certain subcutaneous immunotherapy and other subcutaneous infusion drugs.

• Category 3, covering certain intravenous chemotherapy drugs.

Payment Structure

Medicare pays a single unit of payment per payment category for each infusion drug administration calendar day, which is defined in regulation as a day on which a professional from the qualified home infusion therapy supplier is in the patient's home administering the drug. Payment is 80 percent of the lesser of the actual charge or the fee schedule amount, after the deductible. Rates are higher for the first visit to initiate services and lower for subsequent visits. The HCPCS codes for subsequent visits are G0068, G0069, and G0070, corresponding to categories 1, 2, and 3, and the codes for initial visits are G0088, G0089, and G0090. For 2026, CMS set national rates of $190.22 for G0068, $257.04 for G0069, and $388.89 for G0090, among others, before geographic adjustment.

Because payment depends on a professional's physical presence in the home, days on which the patient self-administers the drug or receives only remote monitoring are not separately payable infusion drug administration calendar days under current law, even though the supplier may provide pharmacy and monitoring services on those days. Pending legislation, such as the Preserving Patient Access to Home Infusion Act, would change this, but suppliers must follow current rules until any change is enacted and implemented.

To bill the higher initial visit rate, the patient must not have received home infusion therapy services in the previous 60 days, and claims must reflect discharge from a prior episode where applicable.

Qualified Home Infusion Therapy Suppliers

Under 42 CFR 414.1505 and 42 CFR Part 486, Subpart I, a qualified home infusion therapy supplier must furnish infusion therapy to individuals with acute or chronic conditions requiring administration of home infusion drugs, ensure the safe and effective provision and administration of home infusion therapy on a seven-day-a-week, 24-hour-a-day basis, be accredited by a CMS-approved accrediting organization, and be enrolled in Medicare as a home infusion therapy supplier. Suppliers that are not accredited and enrolled for this benefit cannot bill home infusion therapy services codes.

Beneficiary Qualifications and Plan of Care

Under 42 CFR 414.1510, to qualify for home infusion therapy services, the beneficiary must be under the care of an applicable provider, which means a physician, nurse practitioner, or physician assistant; the beneficiary must be under a plan of care established and periodically reviewed by that provider that prescribes the type, amount, and duration of infusion therapy services; and the plan of care must contain the elements required by 42 CFR 486.520. The ordering provider must be enrolled in Medicare.

Home IVIG Services

A separate home intravenous immune globulin items and services benefit covers immune globulin and associated items and services for beneficiaries with a diagnosis of primary immune deficiency disease who meet coverage criteria. This benefit has its own billing rules and requirements.

Part D Coverage

Many home infusion drugs that are not covered under the DME benefit are covered under Medicare Part D. Part D covers the drug itself but does not cover the professional services, pumps, or supplies, which creates access challenges. Suppliers must determine which benefit applies to each drug and patient, and must avoid billing Part B for drugs that belong under Part D.

Coordination With Home Health

Patients receiving home infusion may also be under a home health plan of care. Home health agencies are paid under the home health prospective payment system for covered nursing services, and suppliers must coordinate to avoid billing for duplicative services. CMS guidance addresses how home infusion therapy services and home health services interact, and suppliers should confirm current billing rules before furnishing services to patients in a home health episode.

What Auditors Examine

Drug Coverage and Benefit Category

Auditors first confirm that the drug was covered under the benefit billed. For DME claims, they check whether the drug is listed in the External Infusion Pumps LCD for pump administration and whether the patient met the clinical criteria for that drug. For home infusion therapy services claims, they check that the drug falls within a payment category and was administered through a covered pump.

Orders

Auditors check for a standard written order for the pump, drug, and supplies that includes the required elements, such as the beneficiary's name, order date, description of the items, quantity, and the treating practitioner's name or NPI and signature. For home infusion therapy services, they check for the plan of care and orders establishing the type, amount, and duration of services.

Medical Necessity

Auditors review the treating practitioner's medical records for the diagnosis, clinical history, and rationale for home infusion of the specific drug, including any LCD criteria such as failure of or contraindication to other therapies. Records from the treating practitioner are essential; supplier records alone are generally insufficient.

Plan of Care

For home infusion therapy services, auditors review the plan of care to confirm it was established by an applicable provider, includes the required elements, prescribes the services furnished, and was periodically reviewed.

Visit Documentation

Auditors examine nursing and professional visit notes to confirm that a qualified professional was physically present in the home on each billed infusion drug administration calendar day, that the services furnished were consistent with the plan of care, and that the documentation supports the payment category billed.

Proof of Delivery

For DME items and drugs, auditors require proof of delivery that meets Medicare standards, such as signed delivery tickets or shipping records that can be linked to the specific items and patient.

Continued Need and Use

For ongoing therapy, auditors look for documentation that the patient continued to need and use the pump and drug, including refill requests and practitioner records.

Supplier Qualifications

Auditors may verify that the supplier was accredited and enrolled as a qualified home infusion therapy supplier on the dates of service, and that nurses and other professionals were properly licensed.

Documentation Best Practices

Drug and Pharmacy Documentation

• Maintain complete prescriptions and orders that specify the drug, dose, route, frequency, duration, and pump type.

• Document pharmacist clinical review, compounding records, and dispensing records.

• Maintain lot numbers, expiration dates, and delivery records.

• Document the benefit determination for each drug, including why it is billed to DME, home infusion therapy services, Part D, or another payer.

• Obtain and retain clinical documentation from the treating practitioner supporting LCD criteria.

Nursing Documentation

Nursing documentation is the foundation of home infusion therapy services claims. Each visit note should include:

• The date and the time the nurse arrived and departed.

• Confirmation that the visit occurred in the patient's home.

• The drug administered and the nursing activities performed, such as catheter assessment and care, infusion initiation or discontinuation, pump programming, and dressing changes.

• Patient assessment, including vital signs, response to therapy, and adverse reactions.

• Patient and caregiver education provided and their demonstrated understanding.

• Communication with the pharmacist and ordering practitioner.

• The nurse's signature and credentials.

Professional Services and Monitoring

Document remote monitoring, pharmacist monitoring of laboratory values, communications with the patient and practitioner, and changes to therapy. While these services may not each generate separate payment, they demonstrate that the supplier is furnishing the full range of services the benefit requires and support the safety of the therapy.

Plan of Care Management

Ensure the plan of care is established by an applicable provider before services begin, includes required elements, and is reviewed periodically. Document updates when therapy changes, and keep signed copies.

Care Coordination

Document coordination with home health agencies, hospitals, and practitioners, particularly at transitions of care.

Responding to a Home Infusion Audit

Identify the Contractor and Benefit

Determine whether the audit involves DME claims reviewed by a DME MAC or its contractors, home infusion therapy services claims reviewed by an A/B MAC, or a broader program integrity review by a UPIC or OIG. Each benefit has different rules and reviewers.

Assemble Complete Records

For each claim, gather the order or plan of care, treating practitioner records supporting medical necessity, pharmacy records, proof of delivery, nursing visit notes, monitoring records, and documentation of supplier accreditation and enrollment. Request practitioner records promptly.

Review Against Specific Criteria

Compare documentation with the applicable LCD, policy article, and home infusion therapy services regulations. Identify gaps and determine whether additional records can address them.

Submit an Organized Response

Provide an indexed submission with a cover letter explaining how each claim meets coverage requirements.

Appeal Denials

Request redetermination within 120 days of an adverse determination and pursue further levels of appeal as warranted. Submit complete evidence by reconsideration.

Engage Counsel Where Needed

If the audit involves UPIC review, payment suspension, or allegations of fraud, such as billing for visits not provided or drugs not delivered, engage experienced counsel promptly.

Building a Home Infusion Compliance Program

• Verify benefit eligibility and drug coverage at intake.

• Maintain current accreditation and enrollment as a qualified home infusion therapy supplier.

• Use standardized order, plan of care, and visit note templates with required elements.

• Track infusion drug administration calendar days and bill only days with documented in-home professional visits.

• Conduct pre-billing review of high-cost drugs and new referrals.

• Audit a sample of claims regularly for orders, medical necessity, proof of delivery, and visit documentation.

• Train nurses and pharmacists on Medicare documentation requirements.

• Monitor regulatory changes, including implementation of the 2026 DME pump expansion.

• Report and return identified overpayments within 60 days.

Preparing for the 2027 DME Infusion Pump Expansion

Section 6222(a) of the Consolidated Appropriations Act, 2026 directed CMS to expand the DME benefit to include certain external infusion pumps and associated home infusion drugs and supplies, and the CY 2027 home health final rule implements an exception beginning April 1, 2027, for an external infusion pump when the associated home infusion drug is administered under the supervision of a health care professional by a qualified home infusion therapy supplier. Suppliers should review the final rule carefully once published in the Federal Register to understand which drugs and pumps are affected, how coverage criteria will be applied, and what documentation will be required.

New coverage brings new audit exposure. When a benefit expands, contractors typically monitor early claims for errors, and suppliers that move quickly to bill new drugs without fully meeting documentation requirements may see high denial rates. Practical preparation includes updating intake checklists to identify patients who may qualify under the expansion, confirming that the supervising professional's involvement will be documented in a way that matches the regulatory language, training pharmacists and nurses on any new criteria, and updating billing systems to apply the correct codes and modifiers. Suppliers should also watch for DME MAC policy articles and LCD revisions that implement the change.

Common Mistakes

• Billing drugs under the DME benefit when they are not listed in the LCD.

• Missing treating practitioner records supporting LCD criteria.

• Billing home infusion therapy services for days without an in-home professional visit.

• Incomplete or unsigned plans of care.

• Missing proof of delivery for drugs and supplies.

• Billing the initial visit rate when the patient received services within the prior 60 days.

• Failing to coordinate with home health agencies.

Myths About Home Infusion Audits

Myth: Any Drug Infused at Home Is Covered Under Part B

Part B covers home infusion drugs through the DME benefit only when the pump and drug meet LCD criteria. Many drugs are covered under Part D instead.

Myth: Home Infusion Therapy Services Are Paid for Every Day of Therapy

Under current law, payment is made only for infusion drug administration calendar days, when a professional is physically present in the home.

Myth: Pharmacy Records Are Enough to Prove Medical Necessity

Auditors require treating practitioner records documenting the clinical basis for therapy.

Myth: Accreditation Is Optional

Suppliers must be accredited and enrolled as qualified home infusion therapy suppliers to bill the benefit.

Questions Leadership Should Ask

• Do we verify the correct benefit for every drug at intake?

• Are we accredited and enrolled for home infusion therapy services?

• Do our nursing notes document in-home presence and services for every billed day?

• Do we obtain treating practitioner records supporting LCD criteria?

• Are our plans of care complete and reviewed?

• Are we prepared for the 2027 DME pump coverage expansion?

Key Takeaways

• Medicare covers home infusion through the DME external infusion pump benefit, the home infusion therapy services benefit, the home IVIG benefit, and Part D.

• Home infusion therapy services are paid per infusion drug administration calendar day when a professional is in the home, with 2026 rates such as $190.22 for G0068 and $388.89 for G0090.

• Suppliers must be accredited and enrolled, and beneficiaries must be under a plan of care established by a physician, nurse practitioner, or physician assistant.

• Audits focus on drug coverage, orders, medical necessity, plans of care, visit documentation, proof of delivery, and supplier qualifications.

• The 2026 legislative expansion of DME pump coverage takes effect in 2027, and suppliers should prepare now.

How HealthBridge Can Help

HealthBridge helps home infusion pharmacies and qualified home infusion therapy suppliers prepare for and respond to Medicare audits. Our team can review intake and benefit verification processes, audit orders, plans of care, nursing documentation, and proof of delivery against Medicare requirements, design documentation templates, and prepare organized responses and appeals. We also help suppliers prepare for regulatory changes and build internal audit programs. If your organization provides home infusion therapy and wants to strengthen its audit readiness, please get in touch with us. We will be happy to help you with this topic.

References

• Centers for Medicare & Medicaid Services. Home Infusion Therapy / Home IVIG Services. https://www.cms.gov/medicare/payment/fee-for-service-providers/home-infusion-therapy

• Centers for Medicare & Medicaid Services. CY 2026 National Home Infusion Therapy Services Rates. https://www.cms.gov/files/document/cy-2026-national-home-infusion-therapy-services-rates.pdf

• Centers for Medicare & Medicaid Services. Change Request R13512CP, CY 2026 Home Infusion Therapy Services Payment Rates. https://www.cms.gov/files/document/r13512cp.pdf

• Centers for Medicare & Medicaid Services. HIT Monitoring Report (February 2026). https://www.cms.gov/files/document/hit-monitoring-report-feb-2026.pdf

• Federal Register. Medicare Program; CY 2027 Home Health Prospective Payment System Rate Update and DMEPOS Policies Final Rule (public inspection document 2026-22750). https://public-inspection.federalregister.gov/2026-22750.pdf

• Federal Register. CY 2020 Home Health Prospective Payment System Final Rule with Comment Period (84 FR 60478), including home infusion therapy services benefit. https://www.federalregister.gov/documents/2019/11/08/2019-24026

• Electronic Code of Federal Regulations. 42 CFR Part 414, Subpart P, Home Infusion Therapy Services. https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-414/subpart-P

• Electronic Code of Federal Regulations. 42 CFR Part 486, Subpart I, Requirements for Home Infusion Therapy Suppliers. https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-G/part-486/subpart-I

• Electronic Code of Federal Regulations. 42 CFR 410.38, Durable medical equipment: Conditions and limitation on payment. https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-410/subpart-B/section-410.38

• Centers for Medicare & Medicaid Services. Medicare Coverage Database, External Infusion Pumps LCD (L33794) and Policy Article. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=33794

• Centers for Medicare & Medicaid Services. Medicare Program Integrity Manual, Chapter 5, Items and Services Having Special DME Review Considerations. https://www.cms.gov/regulations-and-guidance/guidance/manuals/downloads/pim83c05.pdf

• U.S. Code. 42 U.S.C. 1395x(iii), Home infusion therapy. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section1395x

• Congress.gov. H.R. 7148, Consolidated Appropriations Act, 2026, section 6222. https://www.congress.gov/bill/119th-congress/house-bill/7148

• Congress.gov. H.R. 2172, Preserving Patient Access to Home Infusion Act (119th Congress). https://www.congress.gov/bill/119th-congress/house-bill/2172


Some or all of the services described herein may not be permissible for HealthBridge US clients and their affiliates or related entities.

The information provided is general in nature and is not intended to address the specific circumstances of any individual or entity. While we strive to offer accurate and timely information, we cannot guarantee that such information remains accurate after it is received or that it will continue to be accurate over time. Anyone seeking to act on such information should first seek professional advice tailored to their specific situation. HealthBridge US does not offer legal services.

HealthBridge US is not affiliated with any department of public health agencies in any state, nor with the Centers for Medicare & Medicaid Services (CMS). We offer healthcare consulting services exclusively and are an independent consulting firm not affiliated with any regulatory organizations, including but not limited to the Accrediting Organizations, the Centers for Medicare & Medicaid Services (CMS), and state departments. HealthBridge is an anti-fraud company in full compliance with all applicable federal and state regulations for CMS, as well as other relevant business and healthcare laws. The badges, icons, and achievement graphics displayed on this website represent proprietary performance metrics, volume milestones, and internal corporate recognition issued exclusively by our corporate affiliate network at SummitRidge. These visual markers are utilized solely as historical indicators of enterprise growth, operational longevity, and volume-based milestones cleared within our shared corporate ecosystem.

© 2026 HealthBridge US, a California corporation. All rights reserved.

For more information about the structure of HealthBridge, visit www.myhbconsulting.com/governance

Legal

Resources